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AbstrAct:
While nanoparticles have shown great promise as drug carriers in cancer therapy, 
their effectiveness is critically dependent on the structural characteristics of the 
tumor vasculature. Here we demonstrate that several agents capable of inducing 
vascular  responses  akin  to  those  observed  in  inflammatory  processes  enhance 
the accumulation of nanoparticles in tumors. The vascular-active agents tested in 
this  study  included  a  bacterium,  a  pro-inflammatory  cytokine,  and  microtubule-
destabilizing drugs. Using radiolabeled nanoparticles, we show that such agents 
can increase the tumor to blood ratio of radioactivity by more than 20-fold 
compared to nanoparticles alone. Moreover, vascular-active agents dramatically 
improved the therapeutic effect of nanoparticles containing radioactive isotopes or 
chemotherapeutic agents. This resulted in cures of animals with subcutaneous tumors 
and significantly prolonged the survival of animals with orthotopic brain tumors. 
In principle, a variety of vascular-active agents and macromolecular anticancer 
formulations can be combined, which makes this approach broadly applicable and 
particularly suited for the treatment of patients who have failed standard therapies. 
INtrODUctION 
Wounding results in increased vascular permeability, 
a process that is markedly enhanced if a wound becomes 
infected. In response to infection, the mammalian host 
mobilizes an army of immunoglobulins, complement, 
white blood cells and cytokines. To allow this army to 
engage the enemy, the vascular system at the site of 
infection must open its gates. This process has been 
studied in detail and many of the biochemical mechanisms 
have been identified[1]. 
Interestingly, it has been said that tumors resemble 
“unhealed wounds”[2]. Accordingly, it is known that the 
vasculature of tumors is different from that of normal 
cells, and much effort has gone into exploiting this 
difference through therapeutic agents like Avastin[3-5]. A 
particularly important phenomenon related to this vascular 
distinction is referred to as Enhanced Permeability and 
Retention  (EPR)[6].  EPR  has  been  identified  in  many 
experimental tumor systems and is believed to result from 
the aberrant tumor vasculature combined with a lack of 
functional lymphatics in solid tumors. Because of its 
selectivity for large molecules, EPR has been exploited 
for therapeutic purposes by using macromolecular drugs 
or nanoparticles within an appropriate size range[7-10]. 
One notable example is Doxil, a liposomal formulation of 
doxorubicin, which has been approved for the treatment 
of human cancers. Oncotarget 2011; 2:  59 - 68 60 www.impactjournals.com/oncotarget
Figure 1:  Inflammatory responses enhance tumor-selective accumulation of radiolabeled antibodies.  (A) BALB/c mice 
bearing subcutaneous CT26 tumors were administered C. novyi-NT spores plus 125I-labeled liposomase antibody, CD20 antibody, or an IgG 
control antibody by tail vein injection. The animals were imaged by SPECT/CT 24 hours thereafter. Tumor (Tu), thyroid (Th) and bladder 
(Bl) are indicated. (B, C) Tumor-bearing mice were administered 125I-labeled IgG plus C. novyi-NT spores or TNF-α by tail vein injection. 
For biodistribution analysis (B), mice were sacrificed 48 hours later and percent injected dose per gram of tissue (ID%/g) was determined. 
Means and s.d. are shown. For imaging study (C), SPECT/CT images were taken at the indicated time points after the injections. Tumor (Tu) 
is indicated.Oncotarget 2011; 2:  59 - 68 61 www.impactjournals.com/oncotarget
We wondered whether generating an inflammatory 
environment within a tumor could enhance the EPR 
effect, just as infection within a wound dramatically 
enhances its vascular permeability. To test this approach, 
we determined whether inflammatory and vascular-active 
agents could improve selective nanoparticle accumulation 
within tumors and whether such accumulation would lead 
to improved therapeutic results in animal models. 
resUlts
Bacterial  infection  enhances  antibody 
accumulation in experimental tumors
The research described in this work was stimulated 
by unexpected observations made through the 
investigation of C. novyi-NT, an attenuated anaerobic 
bacterial strain that can infect experimental tumors[11]. 
This infection often leads to eradication of the internal 
hypoxic regions of tumors but leaves the oxygenated 
rim of the tumors intact. C. novyi-NT secretes an enzyme 
called liposomase at high levels in the infected tumors[12, 
13]. We hypothesized that a radiolabeled anti-liposomase 
antibody would synergize with C. novyi-NT by binding to 
liposomase secreted by the bacteria, thereby eradicating 
the oxygenated tumor rim through β-particle irradiation. 
A monoclonal antibody against liposomase was generated 
and used to evaluate this hypothesis (see Methods). 
Mice  bearing  subcutaneous  CT26  tumors  were 
Figure  2:  Inflammatory  responses  enhance  tumor-selective  accumulation  of  radiolabeled  SSLs.  BALB/c  mice  bearing 
subcutaneous CT26 tumors were administered 125I-labeled SSLs plus C. novyi-NT spores or TNF-α by tail vein injection. For biodistribution 
(A), mice were sacrificed 48 hours later and percent injected dose per gram of tissue (ID%/g) was determined. Means and s.d. are shown. For 
imaging analysis (B), SPECT/CT images were taken at the indicated time points after the injections. Tumor (Tu), bladder (Bl) and spleen (Sp) 
are indicated.Oncotarget 2011; 2:  59 - 68 62 www.impactjournals.com/oncotarget
intraveneously injected with C. novyi-NT spores together 
with the radiolabeled anti-liposomase antibody or with 
a  similarly  labeled  IgG  control  antibody.  The  anti-
liposomase antibody was highly enriched in the tumors 
infected with C. novyi-NT but not in uninfected tumors 
(Fig.  1A).  Surprisingly,  however,  the  radiolabeled  IgG 
control antibody was also enriched in the C. novyi-
NT infected tumors, albeit to a lesser extent (Fig. 
1A).  Biodistribution  analyses  showed  that  the  level  of 
radioactivity in the tumor was four-fold higher than that 
in most normal tissues (Fig. 1B). 
To further confirm that the accumulation in the tumors 
was not antibody-specific, we repeated the experiment with 
another antibody generated against human CD20, a B-cell 
antigen. The partially humanized version of this antibody, 
Rituximab, has been marketed for the treatment of B cell 
lymphoma  and  chronic  lymphocytic  leukemia[14,  15]. 
Systemically administered anti-CD20 antibody was also 
enriched in the tumor if the animal was simultaneously 
injected with C. novyi-NT spores (Fig. 1A). 
Bacterial infection and pro-inflammatory cytokine 
both  enhance  tumor-selective  accumulation  of 
macromolecular drug formulations
We  reasoned  that  the  inflammatory  response  to 
the bacterial infection led to an increased vascular 
permeability, resulting in the preferential antibody 
accumulation at the infected tumor site. We therefore 
sought  to  identify  a  pro-inflammatory  cytokine  that 
might mimic the effects of C. novyi-NT. Among those 
considered,  Tumor  Necrosis  Factor-α  (TNF-α)  was  of 
particular  interest  as  this  cytokine  has  been  identified 
as  the  serum  factor  responsible  for  endotoxin-induced 
vascular permeabilization[16, 17]. Furthermore, a similar 
hemorrhagic necrosis in tumors is observed following 
systemic administration of either TNF-α or C. novyi-NT 
spores[11,  16]. Based on these parallels, we repeated 
the protocol described above, substituting systemically-
administered TNF-α for C. novyi-NT spores. When CT26 
tumor-bearing mice were injected with murine TNF-α and 
radiolabeled  murine  IgG,  significant  IgG  accumulation 
was observed in the tumors but not in the normal tissues 
(Fig. 1B and C). A time course study revealed that the 
IgG tumor accumulation progressed slowly and peaked 
between 72 and 96 hours after injection (Fig. 1C). 
The  effect  of  vascular-active  agents  on  tumor 
vasculature will henceforth be referred to as Enhanced 
EPR (E2PR). Sterically stabilized liposomal nanoparticles 
(SSLs) of ~100 nm in diameter have been shown to be 
susceptible  to  the  EPR  effect[8].  To  evaluate  whether 
such liposomes were susceptible to E2PR, we fabricated 
radioactive  liposomes  using  a  Bolton-Hunter  (BH) 
reagent-based  iodination  strategy[18].  Iodinated  BH 
reagent labels proteins by forming amide bonds with 
free amino groups such as those present on arginine[19]. 
SSLs were loaded with arginine at low pH and then the 
loaded SSLs were incubated with 125I-labeled BH reagent. 
The 125I-BH reagent passed through the lipid bilayer but 
was unable to exit after covalent binding to the arginine 
because of the latter’s positive charge. We were thus 
able to achieve a very high concentration of radioactivity 
within the SSLs while avoiding prolonged exposure to the 
radioactivity during the preparation. 
125I-labeled SSLs were intravenously injected into 
tumor-bearing mice in combination with either C. novyi-
NT or TNF-α. Both C. novyi-NT and TNF-α treatments 
significantly  augmented  the  selective  retention  of  125I 
within  tumors  (Fig.  2).  Furthermore,  the  radioactivity 
in normal tissues was markedly lower compared to the 
animals treated with 125I-labeled SSLs without TNF-α or 
C. novyi-NT (Fig. 2A). Thus, the tumor-to-blood ratio of 
radioactivity following TNF-α treatment was as high as 
22-fold, far higher than achieved with radiolabeled IgG 
(compare Fig. 2A to Fig. 1B). SPECT/CT also revealed 
that the kinetics of tumor accumulation was different 
with radiolabeled SSLs than with IgG: SSL accumulation 
peaked at 24 hours, 48 - 72 hours earlier than IgG. 
Like  EPR,  the  effect  of  E2PR  is  particle  size-
dependent. In contrast to 125I-labeled SSLs, tumor retention 
of  125I-labeled arginine (the substrate of  125I labeling in 
SSLs) is not affected by TNF-α. However, at the other 
end of the size spectrum, 125I-labeled C. novyi-NT spores 
(~1 µm in diameter[20]) are highly enriched in tumors 
only  when  combined  with  TNF-α  (data  not  shown). 
Thus, E2PR appears to reflect a more substantial vascular 
disruption  than  EPR:  while  EPR  favors  accumulation 
of nanoparticles in the range around 100 nm[8], E2PR 
extends that range to >1 µm.
To determine whether the accumulation was 
dependent on the volume of the tumor, we injected TNF-α 
plus  125I-labeled  IgG  or  125I-labeled  SSLs  into  animals 
with a small subcutaneous tumor on one flank and a large 
tumor on the other flank. SPECT/CT showed retention of 
radioactivity in both tumors (examples in Supplementary 
Fig. S1). We also tested the relative timing of injection of 
TNF-α and  125I-labeled SSLs. Though TNF-α and SSLs 
were administered jointly in the experiments recorded 
above, we found that similar results were obtained when 
TNF-α  was  administered  within12  hours  after  SSLs. 
Conversely, E2PR  was  not  observed  when  TNF-α  was 
administered 6 hours prior to SSL administration (data not 
shown).
Microtubule-interacting  agents  are  also  able  to 
disrupt the tumor vasculature[21]. We therefore determined 
whether such agents could induce E2PR. Combretastatin 
A4P (CA4P) and vinorelbine are microtubule-interacting 
agents with completely different structures and modes of 
interaction with microtubules[22, 23]. Injection of either 
resulted in E2PR, though not as impressively as TNF-α 
(Supplementary Fig. S2). Oncotarget 2011; 2:  59 - 68 63 www.impactjournals.com/oncotarget
TNF-α  and  macromolecular  drug  formulations 
synergize in the treatment of experimental tumors
We next investigated whether the E2PR could 
be translated into therapeutic gain. Mice bearing fully 
developed CT26 tumors were treated by simultaneous i.v. 
injections of TNF-α plus Doxil (10 mg/kg) or radiolabeled 
IgG. 131I rather than 125I was chosen for radiolabeling in 
light of the type of ionizing radiation required for a 
radiotherapeutic effect. Although treatment with Doxil or 
131I-labeled IgG in the absence of TNF-α retarded tumor 
growth and prolonged animal survival, the tumors always 
grew back (Fig. 3A and B). When combined with TNF-α, 
however, a single administration of these agents led to 
complete tumor regression in all animals and long-term 
cures in more than 75% of them. When a lower dose (25 
µg/kg) of TNF-α was used, none of the treated animals 
were cured, although prolonged survival was observed. 
It is important to note that humans tolerate multiple 
injections (3 infusions/week) of a dose comparable to the 
highest dose of TNF-α we used[24]. We also tested SSLs 
containing  131I, generated using the chemical trapping 
approach described above. While 131I-labeled  SSLs 
alone retarded tumor growth, complete tumor regression 
and cures were only observed when they were used in 
combination with TNF-α (Fig. 3C).
Finally, we evaluated the therapeutic potential of 
E2PR in a murine model of glioblastoma multiforme 
(GBM). When implanted orthotopically, the brain tumor 
cell  line  GL261  forms  very  aggressive  tumors,  killing 
animals within about a month (Fig. 4A). At the histologic 
level,  these  tumors  are  very  similar  to  human  GBM, 
manifesting an infiltrative growth pattern, necrosis and 
neovascularization[25].  Following  stereotactic  injection 
of GL261 cells into the frontal lobe, brain tumors were 
allowed to grow to substantial size, then 125I-labeled 
SSLs with or without TNF-α were administered. Tumor 
accumulation of the radiolabeled SSLs was only observed 
in TNF-α treated animals (Fig. 4B). Mice with similar 
tumors were injected with Doxil, either with or without 
TNF-α. The combination clearly had a therapeutic benefit, 
prolonging survival up to 103 days even in this highly 
challenging pre-clinical model (Fig. 4A). Both Doxil and 
Figure 3: TNF-α enhances the antitumor activity of macromolecular drug formulations. Tumor-bearing mice were treated 
on day 0 with a single dose of the combinations of TNF-α plus 131I-labeled IgG (A), Doxil (B), or 131I-labeled SSLs (C), respectively. The 
therapeutic effects on tumor volume and animal survival are shown. Means and s.e.m. are illustrated. The number of animals used in each 
experimental arm is shown in parentheses. P values between arms are also shown.Oncotarget 2011; 2:  59 - 68 64 www.impactjournals.com/oncotarget
TNF-α showed limited therapeutic benefit when used as 
single agents, with no animal surviving beyond 50 days 
following tumor implantation.
DIscUssION
The major limitation for most chemotherapeutic 
agents is their toxicity toward normal tissues, which 
prohibits the use of doses high enough to eradicate all 
cancer cells. One approach to address this problem is 
to develop agents that are delivered to all cells but are 
preferentially toxic to tumor cells because of the abnormal 
signaling pathways. This strategy underlies the success of 
agents such as Gleevec (imatinib) and Iressa (gefitinib)
[26, 27]. A second approach is to use agents that bind to 
extracellular molecules present at higher concentrations on 
the surface of tumor cells, such as Herceptin (trastuzumab) 
and Erbitux (cetuximab)[28, 29]. The third approach takes 
advantage of the abnormal vasculature present in tumors, 
allowing preferential accumulation of nanoparticles (the 
EPR effect)[6, 30]. Though all approaches have merit, the 
third has the advantage that virtually any drug, including a 
wealth of clinically approved agents, can in theory be made 
more effective by their incorporation into nanoparticles of 
appropriate sizes. The ability to use agents that are already 
clinically approved poses many practical advantages 
with respect to the performance of clinical trials and the 
duration of the drug approval process. 
In this work, we have attempted to enhance the third 
approach through pharmacologic manipulation of the 
abnormal vasculature already present in tumors. We show 
that E2PR can dramatically increase the tumor:blood ratio 
of nanoparticles, as assessed by biodistribution, and we 
hypothesize that this increase is primarily responsible for 
the enhanced therapeutic response. It is worth noting that 
even a small difference in the intratumoral concentration 
of an agent can make a large difference in therapeutic 
effect[31].  In  the  studies  described  here,  E2PR led to 
Figure 4: Vascular effect of TNF-α on a brain tumor model. (A) C57BL6 mice bearing orthotopic brain tumors were treated with 
a single dose of the indicated therapeutic agents 12 days after tumor implantation. The number of animals used in each experimental arm and 
P values between arms are shown. (B) SPECT-CT images were obtained 48 hours following the indicated treatments, which were performed 
25 days following tumor implantation. Transverse, coronal, and sagittal images are shown and tumors indicated by the arrowheads. In this 
particular animal, two tumor nodules developed along the injection track and both showed tumor accumulation of 125I-labeled SSLs when 
TNF-α was co-administered.Oncotarget 2011; 2:  59 - 68 65 www.impactjournals.com/oncotarget
a  tumor:blood  ratio  of  more  than  22-fold  (Fig.  2A). 
However,  it  should  be  noted  that TNF-α,  C. novyi-NT 
infection, and doxorubicin-induced cancer cell apoptosis 
are all able to induce or enhance a host immune response 
that could have contributed to the observed therapeutic 
response.
We were particularly encouraged with the results 
in the GBM model. This tumor type in humans is highly 
recalcitrant to conventional therapies, leading to a dismal 
prognosis for patients with this disease. The blood-brain 
barrier is at least partly to blame for the limited efficacy of 
chemotherapy[32]. We found that TNF-α treatment could 
help breach the blood-brain barrier and result in major 
accumulations of 125I-labeled SSLs in the orthotopically 
implanted brain tumors as well as significantly prolong 
the survival of the tumor-bearing animals (Fig. 4). As the 
mouse cranial cavity is small, murine brain tumors are 
particularly difficult to treat as even a minimal amount of 
growth of a pre-existing tumor is lethal. 
In sum, our results suggest a way to improve the 
therapeutic efficacy of conventional and novel drugs by 
incorporating them into nanoparticles and injecting them 
together with vascular-active agents such as TNF-α. The 
approach is versatile, as it should be practicable with a 
variety of nanoparticle formulations as well as with 
diverse chemical and radioactive agents. Different classes 
of agents with E2PR effect can be employed to enhance 
their tumor accumulation. In addition to those tested in 
this work, other vasoactive agents, including vascular 
endothelial  growth  factor  (VEGF),  are  likely  to  have 
similar effect. An imaging-based companion test may be 
developed in the future to assess which vasoactive agent is 
most effective, as the vasculature of individual cancers may 
have varied sensitivity to a specific vascular-active agent. 
Future clinical trials can address whether this strategy is 
as efficacious in humans as it is in mice. To accelerate 
the translation of this approach, we have intentionally 
used TNF-α at doses either below or comparable to the 
maximum tolerated dose (MTD) as defined in a number 
of clinical trials [33].
MAterIAls AND MethODs
Cell Lines
CT26 (CRL-2638) murine colorectal adenocarcinoma 
cells  were  purchased  from  the American Type  Culture 
Collection (ATCC) and grown in McCoy’s 5A Medium 
(Invitrogen) supplemented with 10% Fetal Bovine Serum 
(FBS, HyClone) at 37°C with 5% CO2. GL261 glioma 
cells were kindly provided by Dr. Michael Lim (Johns 
Hopkins University, Baltimore) and maintained in DMEM 
media (ATCC) supplemented with 10% FBS.
Reagents
Bolton-Hunter  reagent  (BH,  N-succinimidyl-3-
(4-hydoxyphenyl)-propionate)  and  TNF-α  (mouse, 
recombinant)  were  purchased  from  Sigma-Aldrich. 
Radioiodines (Sodium 125- or 131-iodide) were purchased 
from MP Biomedicals and Nordion, respectively. IODO-
GEN was purchased from Pierce. Mouse monoclonal IgG1 
isotype control antibody (ab18447) and CD20 antibody 
(ab8237)  were  purchased  from  Abcam.  PEGylated 
liposomal doxorubicin (DOXIL®) was purchased from 
Tibotec Therapeutics. Hydrogenated Chicken Egg L-α-
Phosphatidylcholine (HEPC), 1,2-Distearoyl-sn-Glycero-
3-Phosphoethanolamine-N-[Methoxy(Polyethylene 
glycol)-2000] (DSPE-PEG2000) and Cholesterol (Chol) 
were purchased from Avanti Polar Lipids. C. novyi-NT 
spores were prepared as previously described [11]. 
Animal models
All animal experiments were overseen and approved 
by  the  Animal  Welfare  Committee  of  Johns  Hopkins 
University, and were in compliance with the University 
standards. For the subcutaneous tumor model, female, 
six  to  eight  week-old  BALB/c  mice  (Harlan  Breeders, 
~20 g in weight) were used. Five million CT26 cells were 
injected subcutaneously into the right flank of each mouse 
and allowed to grow for ~10 days before randomization, 
group assignment, and treatment. C. novyi-NT spores 
were administered by a bolus tail vein injection of 300 
million spores suspended in 0.2 mL of phosphate buffered 
saline, pH 7.5 (PBS). Cytotoxic anticancer agents were 
administered 16 hours later via the same route. TNF-α 
was reconstituted freshly before administration in doubly-
distilled H2O at 100 µg/mL and diluted into 0.1% (w/v) 
BSA in PBS at a final concentration of 10 µg/mL. Cytotoxic 
agents were injected within a few minutes thereafter. 
Tumor volume was calculated as length x width2 x 0.5. For 
the orthotopic brain tumor model, female C57BL6 mice, 
5-6 weeks of age, were purchased from the NCI-Frederick. 
Mice were anesthetized via intraperitoneal injection of 60 
µL of a stock solution containing ketamine hydrochloride 
(75 mg/kg, Abbot Laboratories), xylazine (Xyla-ject®, 7.5 
mg/kg, Phoenix Pharmaceutical), and ethanol (14.25%) in 
a sterile 0.9% NaCl solution. Following a 1-cm midline 
scalp incision, a 1-mm burr hole was placed over the right 
frontal bone, with its center 2 mm lateral to the sagittal 
suture  and  1  mm  anterior  to  the  coronal  suture.  On  a 
stereotactic  frame,  a  sterile  needle  loaded  with  20,000 
GL261 cells was placed at a depth of 3 mm below the dura 
and the cells were injected slowly at a rate of 1 µL/minute. 
Afterwards, the animal was removed from the frame and 
the scalp incision closed with surgical staples. On day 
12  post  implantation  of  the  tumor  cells,  a  significant 
tumor  was  formed  and  1  µg  of  mouse  recombinant Oncotarget 2011; 2:  59 - 68 66 www.impactjournals.com/oncotarget
TNF-α or 100 µL of Doxil at 20 mg/kg, or both, were 
administered intravenously through the tail vein. Animals 
were monitored for potential side effects following drug 
administration. Animals were observed daily for any signs 
of deterioration, neurotoxicity, or movement disorders. 
They were inspected for signs of pain and distress, as per 
the Johns Hopkins Animal Care and Use Guidelines. If 
the symptoms persisted and resulted in debilitation, the 
moribund animals were euthanized. The brain and other 
organs were dissected and placed in formalin for further 
pathological studies. A single dose was administered for 
all therapeutic agents described above.
Liposomase Antibody
Three  peptides  (JHU009A:  CNVDLQQKLIEN; 
JHU009B:  CYPEWGTKDENGNIRK;  JHU009C: 
CDMAQMLRNLPVTE) were used to immunize the mice 
for generating antibodies against C. novyi-NT liposomase 
(A&G Pharmaceutical). After screening ~500 hybridoma 
clones by ELISA, one clone (JHU009-5F5) specific to the 
JHU009C peptide was eventually selected for the imaging 
study.  The  affinity  and  specificity  of  the  JHU009-5F5 
mAb were also confirmed by both ELISA and western 
blot analyses against purified liposomase protein [12].
Radioiodination of Antibodies
Typically,  20  µg  of  purified  antibody  in  100  µL 
of  PBS  was  added  to  an  iodogen-coated  vial.  Sodium 
125- or 131-iodide was then added to the vial at 2 to 5 
mCi in 2 to 5 µL of 0.1 M NaOH, pH 10. The reaction 
was then incubated for 10 minutes at room temperature 
before purification on a PBS-equilibrated Sephadex G-25 
desalting  column  (Amersham  Biosciences)  to  remove 
unincorporated radioiodine. The radiochemical yield was 
typically 30% to 40%. The radiochemical purity was at 
least 95% as determined by thin-layer chromatography. 
Antibodies were labeled within 24 hours of use and stored 
in PBS at 4°C after labeling and purification.
Preparation of Liposomes
A mixture of HEPC:Chol:DSPE-PEG2000 at a molar 
ratio of 50:45:5 was solubilized in chloroform, followed 
by drying to a thin film under rotary evaporation and then 
under vacuum for 2 hours. The film was hydrated with 
arginine  solution  (80  mmol/L)  in  4-(2-hydroxyethyl)-
piperazine-1-sulphonic  acid  (HEPES,  80  mmol/L,  pH 
8.0) and submerged in a 65°C sonication bath (Bransonic) 
to form Large Multilamellar Vesicles (MLVs). This lipid 
suspension was extruded 10 times through a double stack 
of  0.1  µm  Nuclepore  filters  (Whatman)  using  a  Lipex 
Thermobarrel Extruder (Northern Lipids). The resulting 
colloidal  suspension  of  Single  Unilamellar  Vesicles 
(SUV) was dialyzed against 150 mmol/L phosphate buffer 
(pH 5.6) at 4°C to exchange the external milieu of the 
liposomes and then filter-sterilized. The mean size of the 
SUVs was ~100 nm in diameter and polydispersity index 
~0.1 as determined by quasi-elastic light scattering using 
a Malvern Zetasizer 3000 (Malvern).
Radioiodination of Bolton-Hunter reagent
Bolton-Hunter reagent (BH, N-hydroxysuccinimide 
(NHS) ester of HPPA) was labeled with sodium 125- or 
131-iodide by the chloramine-T method and purified by 
solvent extraction. Briefly, 50 µL of chloramine T (4 mg/
mL in phosphate buffer) and 3.7 to 37 MBq (0.1–1.0 mCi) 
of 125I-NaI or 131I-NaI were added to 2 µL of BH freshly 
solubilized in anhydrous dioxin (0.5 mg/mL). Iodination 
was achieved by incubation at room temperature for 
approximately 15 sec and then 400 µL of 100 mmol/L 
phosphate buffer (pH 7.4) was added. The radiolabeled 
BH was immediately extracted with 500 µL of toluene and 
the organic phase was removed and transferred to a glass 
tube. For the encapsulation of the reagent into liposomes, 
the organic solvent was evaporated using a dry nitrogen 
stream before adding the liposome suspension.
Encapsulation of the Iodinated Reagents into the 
Liposomes
For the chemical entrapment of the iodinated BH, 
arginine-containing  liposomes  were  incubated  for  30 
min at 37°C with  125I-BH. The labeling efficiency was 
determined by counting the liposome suspension before 
and  after  chromatography  on  a  PD-10  column  (GE 
Healthcare)[18]. The radiochemical yield was typically 
50% to 70%.
Biodistribution Assay
CT26-bearing BALB/c mice were injected via the 
tail vein with 50 µCi of 125I-liposomes or 125I-IgG1. Three 
to four mice in each experimental arm were sacrificed 
by  cervical dislocation at  48  hours  post  injection. The 
liver, spleen, kidneys, muscle, and tumor were quickly 
removed as was ~0.1 mL of blood. The organs and blood 
were weighed and their radioactivity was measured with 
an automated gamma counter (1282 Compugamma CS, 
Pharmacia/LKB Nuclear). The percent injected dose per 
gram  of  tissue  (ID%/g)  was  calculated  by  comparison 
with samples of a standard dilution of the initial dose. All 
measurements were corrected for decay.Oncotarget 2011; 2:  59 - 68 67 www.impactjournals.com/oncotarget
SPECT-CT Imaging
BALB/c mice bearing subcutaneous CT26 tumor or 
C57BL6 mice bearing orthotopic GL261 brain tumor were 
injected intravenously with 37.5 MBq (1 mCi) of either 
125I-IgG1 or 125I-SSLs in saline. The mice were positioned 
on  the  X-SPECT  (Gamma  Medica-Ideas)  gantry  and 
scanned using two low-energy, high resolution pinhole 
collimators (Gamma Medica-Ideas) rotating through 360o 
in 6o increments for 40 seconds per increment. Immediately 
following SPECT acquisition, the mice were scanned by 
CT (X-SPECT) over a 4.6 cm field of view using a 600 
mA,  50  kV  beam.  Data  were  reconstructed  using  the 
ordered  subsets-expectation  maximization  algorithm. 
The SPECT and CT data were then coregistered using the 
instrument supplied software and displayed using AMIDE 
(http://amide.sourceforge.net/) or Amira software (Visage 
Imaging).
Statistical Analysis
The  statistical  significance  of  percent  survival 
between different experimental arms was determined by 
Long-rank analysis.
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